Interstitial Cystitis Market Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2030 | Lipella Pharmaceuticals, Purdue Pharma, Alivio Therapeutics, Seikagaku Corporation, Kyorin Holdings and Many More
DelveInsight has launched a report on “Interstitial Cystitis - Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight's "Interstitial Cystitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
Key facts of the report:
Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis-market
“As per DelveInsight’s analysis, the estimates suggest higher prevalence of the disease among the females throughout the 7MM”
According to the Urology Care Foundation, Interstitial cystitis/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain occurs in the lower urinary tract, which last for more than 6 weeks, without having an infection or other clear causes. It is a chronic, or long-lasting condition that causes painful urinary symptoms.
According to Interstitial Cystitis Association, currently here are two recognized subtypes of Interstitial cystitis: Non ulcerative and Ulcerative.
The exact cause of the disease is not known, but there are certain theories, such as a defect in the bladder tissue, which may allow irritating substances in the urine to penetrate the bladder, a specific type of inflammatory cell, called a mast cell. This cell releases histamine and other chemicals that lead to IC/BPS symptoms, changes in the nerves that carry bladder sensations, so pain is caused by events that are generally not painful, the body's immune system attacks the bladder which is similar to other autoimmune conditions.
The symptoms include pain in pelvis or between the vagina and anus in women, and between the scrotum and anus in men (perineum), along with chronic pelvic pain, a persistent, urgent need to urinate, frequent urination—often of small amounts—throughout the day and night (up to 60 times a day), pain or discomfort while the bladder fills, and relief after urinating.
Some of the key companies working on Interstitial Cystitis are:
The launch of the emerging therapies is expected to significantly impact the Interstitial Cystitis treatment scenario in the upcoming years:-
Drugs Covered:
Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis-market
Table of Contents:
3.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2030
4.2. Causes
4.3. Risk Factors
4.4. Signs and Symptoms
4.5. Pathophysiology
4.6. Biomarkers for patients with interstitial cystitis
4.7. Diagnosis
4.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS
4.7.2. American Urology Association diagnosis guideline
4.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline
5.2. Key Findings
5.3. 7MM Total Prevalent Patient Population of Interstitial Cystitis
5.4. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Interstitial Cystitis in the United States
6.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States
6.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States
6.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.2.2. Germany
6.2.2.1. Total Prevalent Population of Interstitial Cystitis in Germany
6.2.2.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany
6.2.2.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany
6.2.2.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany
6.2.3. France
6.2.3.1. Total Prevalent Population of Interstitial Cystitis in France
6.2.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France
6.2.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in France
6.2.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France
6.2.4. Italy
6.2.4.1. Total Prevalent Population of Interstitial Cystitis in Italy
6.2.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy
6.2.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy
6.2.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy
6.2.5. Spain
6.2.5.1. Total Prevalent Population of Interstitial Cystitis in Spain
6.2.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain
6.2.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain
6.2.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain
6.2.6. United Kingdom
6.2.6.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom
6.2.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom
6.2.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom
6.2.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
6.3. Japan
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Interstitial Cystitis in Japan
6.3.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan
6.3.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan
6.3.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan
7.2. Treatment Algorithm
7.2.1. United States
7.2.2. Japan
7.2.3. Europe
9.1.1. Drug Description
9.1.2. Mechanism of action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Product Profile
10.1.1. Drug Description
10.1.2. Mechanism of Action
10.1.3. Regulatory Milestones
10.1.4. Advantages & Disadvantages
10.1.5. Safety and Efficacy
10.1.6. Product Profile
10.2. Cystistat: Bioniche Life Sciences Inc
10.2.1. Drug Description
10.2.2. Mechanism of Action
10.2.3. Regulatory Milestones
10.2.4. Advantages & Disadvantages
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Gepan instill: Pohl-Boskamp GmbH
10.3.1. Drug Description
10.3.2. Mechanism of Action
10.3.3. Advantages & Disadvantages
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Uracyst: Stellar Pharmaceuticals
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Advantages & Disadvantages
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.4.6. Drug Description
10.4.7. Advantages & Disadvantages
10.4.8. Safety and Efficacy
10.4.9. Product Profile
10.5. iAluRil: Aspire Pharma
10.5.1. Drug Description
10.5.2. Mechanism of Action
10.5.3. Advantages & Disadvantages
10.5.4. Safety and Efficacy
10.5.5. Product Profile
List to be continued in the report...
11.2. KRP-116D: Kyorin Holdings
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile
11.3. SI-722: Seikagaku Corporation
11.3.1. Product Description
11.3.2. Clinical Development
11.3.3. Product Profile
11.4. LP-08: Lipella Pharmaceuticals
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Safety and Efficacy
11.4.5. Product Profile
List to be continued in the report...
12.2. Market Size of Interstitial Cystitis in 7MM
13.1.1. Total Market size of Interstitial Cystitis in the United States
13.1.2. Market Size by Current Therapies in the United States
13.1.3. Market Size by Emerging Therapies in the United States
14.1.1. Total Market size of Interstitial Cystitis in Germany
14.1.2. Market Size by Current Therapies in Germany
14.1.3. Market Size by Emerging Therapies in Germany
14.2. France
14.2.1. Total Market size of Interstitial Cystitis in France
14.2.2. Market Size by Current Therapies in France
14.2.3. Market Size by Emerging Therapies in France
14.3. Italy
14.3.1. Total Market size of Interstitial Cystitis in Italy
14.3.2. Market Size by Current Therapies in Italy
14.3.3. Market Size by Emerging Therapies in Italy
14.4. Spain
14.4.1. Total Market Size of Interstitial Cystitis in Spain
14.4.2. Market Size by Current Therapies in Spain
14.4.3. Market Size by Emerging Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom
14.5.2. Market Size by Current Therapies in the United Kingdom
14.5.3. Market Size by Emerging Therapies in the United Kingdom
15.2. Market Size by Current Therapies in Japan
15.3. Market Size by Emerging Therapies in Japan
Related Reports:
Interstitial Cystitis - Pipeline Insights, 2020
The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
Interstitial Cystitis - Epidemiology Forecast to 2030
The Interstitial Cystitis epidemiology covered in the report provides historical as well as forecasted Interstitial Cystitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
DelveInsight's "Interstitial Cystitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
- According to DelveInsight, the total prevalent population of Interstitial Cystitis in the Seven Major Markets was approximately 8,517,779 in 2017.
- In the epidemiology model, the analystsreported a higher prevalence of Interstitial Cystitis the United States with around 5,000,101 prevalent cases in 2017.
- Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 844,367 cases.
- Spain had the lowest prevalent population of 4,95,983 in 2017.
Key facts of the report:
- Interstitial Cystitis market report covers a descriptive overview and comprehensive insight of the Interstitial Cystitis epidemiology and Interstitial Cystitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- Interstitial Cystitis market report provides insights on the current and emerging therapies.
- Interstitial Cystitis market report offers a global historical and forecasted market covering drug outreach in 7MM.
- Interstitial Cystitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market.
Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis-market
“As per DelveInsight’s analysis, the estimates suggest higher prevalence of the disease among the females throughout the 7MM”
According to the Urology Care Foundation, Interstitial cystitis/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain occurs in the lower urinary tract, which last for more than 6 weeks, without having an infection or other clear causes. It is a chronic, or long-lasting condition that causes painful urinary symptoms.
According to Interstitial Cystitis Association, currently here are two recognized subtypes of Interstitial cystitis: Non ulcerative and Ulcerative.
The exact cause of the disease is not known, but there are certain theories, such as a defect in the bladder tissue, which may allow irritating substances in the urine to penetrate the bladder, a specific type of inflammatory cell, called a mast cell. This cell releases histamine and other chemicals that lead to IC/BPS symptoms, changes in the nerves that carry bladder sensations, so pain is caused by events that are generally not painful, the body's immune system attacks the bladder which is similar to other autoimmune conditions.
The symptoms include pain in pelvis or between the vagina and anus in women, and between the scrotum and anus in men (perineum), along with chronic pelvic pain, a persistent, urgent need to urinate, frequent urination—often of small amounts—throughout the day and night (up to 60 times a day), pain or discomfort while the bladder fills, and relief after urinating.
Some of the key companies working on Interstitial Cystitis are:
- Lipella Pharmaceuticals
- Purdue Pharma/Alivio Therapeutics
- Seikagaku Corporation
- Kyorin Holdings
The launch of the emerging therapies is expected to significantly impact the Interstitial Cystitis treatment scenario in the upcoming years:-
Drugs Covered:
- LP-08
- ALV-107
- SI-722
- KRP-116D
Request for Sample Pages: https://www.delveinsight.com/sample-request/interstitial-cystitis-market
Table of Contents:
- Key Insights
- Executive Summary of Interstitial Cystitis
- Interstitial Cystitis: Market Overview at a Glance
3.2. Total Market Share (%) Distribution of Interstitial Cystitis in 2030
- Interstitial Cystitis (IC): Disease Background and Overview
4.2. Causes
4.3. Risk Factors
4.4. Signs and Symptoms
4.5. Pathophysiology
4.6. Biomarkers for patients with interstitial cystitis
4.7. Diagnosis
4.7.1. Consensus panel recommendations for the evaluation and diagnosis of patients with suspected IC/PBS
4.7.2. American Urology Association diagnosis guideline
4.7.3. Society of Interstitial Cystitis of Japan (SICJ) diagnosis guideline
- Epidemiology and Patient Population
5.2. Key Findings
5.3. 7MM Total Prevalent Patient Population of Interstitial Cystitis
5.4. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis
- Country Wise-Epidemiology of Interstitial Cystitis
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Interstitial Cystitis in the United States
6.1.3. Sex-Specific Prevalent Population of Interstitial Cystitis in the United States
6.1.4. Total Diagnosed Prevalence of Interstitial Cystitis in the United States
6.1.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.2.2. Germany
6.2.2.1. Total Prevalent Population of Interstitial Cystitis in Germany
6.2.2.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Germany
6.2.2.3. Total Diagnosed Prevalence of Interstitial Cystitis in Germany
6.2.2.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany
6.2.3. France
6.2.3.1. Total Prevalent Population of Interstitial Cystitis in France
6.2.3.2. Sex-Specific Prevalent Population of Interstitial Cystitis in France
6.2.3.3. Total Diagnosed Prevalence of Interstitial Cystitis in France
6.2.3.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in France
6.2.4. Italy
6.2.4.1. Total Prevalent Population of Interstitial Cystitis in Italy
6.2.4.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Italy
6.2.4.3. Total Diagnosed Prevalence of Interstitial Cystitis in Italy
6.2.4.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy
6.2.5. Spain
6.2.5.1. Total Prevalent Population of Interstitial Cystitis in Spain
6.2.5.2. Sex-Specific Prevalent Population of Interstitial Cystitis in Spain
6.2.5.3. Total Diagnosed Prevalence of Interstitial Cystitis in Spain
6.2.5.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain
6.2.6. United Kingdom
6.2.6.1. Total Prevalent Population of Interstitial Cystitis in the United Kingdom
6.2.6.2. Sex-Specific Prevalent Population of Interstitial Cystitis in the United Kingdom
6.2.6.3. Total Diagnosed Prevalence of Interstitial Cystitis in the United Kingdom
6.2.6.4. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
6.3. Japan
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Interstitial Cystitis in Japan
6.3.3. Sex-Specific Prevalent Population of Interstitial Cystitis in Japan
6.3.4. Total Diagnosed Prevalence of Interstitial Cystitis in Japan
6.3.5. Severity Specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan
- Treatment Algorithm, Current Treatment, and Medical Practices
7.2. Treatment Algorithm
7.2.1. United States
7.2.2. Japan
7.2.3. Europe
- Unmet Needs
- Marketed Drugs
9.1.1. Drug Description
9.1.2. Mechanism of action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Product Profile
- Instillations
10.1.1. Drug Description
10.1.2. Mechanism of Action
10.1.3. Regulatory Milestones
10.1.4. Advantages & Disadvantages
10.1.5. Safety and Efficacy
10.1.6. Product Profile
10.2. Cystistat: Bioniche Life Sciences Inc
10.2.1. Drug Description
10.2.2. Mechanism of Action
10.2.3. Regulatory Milestones
10.2.4. Advantages & Disadvantages
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Gepan instill: Pohl-Boskamp GmbH
10.3.1. Drug Description
10.3.2. Mechanism of Action
10.3.3. Advantages & Disadvantages
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Uracyst: Stellar Pharmaceuticals
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Advantages & Disadvantages
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.4.6. Drug Description
10.4.7. Advantages & Disadvantages
10.4.8. Safety and Efficacy
10.4.9. Product Profile
10.5. iAluRil: Aspire Pharma
10.5.1. Drug Description
10.5.2. Mechanism of Action
10.5.3. Advantages & Disadvantages
10.5.4. Safety and Efficacy
10.5.5. Product Profile
List to be continued in the report...
- Emerging Therapies
11.2. KRP-116D: Kyorin Holdings
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile
11.3. SI-722: Seikagaku Corporation
11.3.1. Product Description
11.3.2. Clinical Development
11.3.3. Product Profile
11.4. LP-08: Lipella Pharmaceuticals
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Safety and Efficacy
11.4.5. Product Profile
List to be continued in the report...
- Interstitial Cystitis: 7 Major Market Analysis
12.2. Market Size of Interstitial Cystitis in 7MM
- The United States Market Outlook
13.1.1. Total Market size of Interstitial Cystitis in the United States
13.1.2. Market Size by Current Therapies in the United States
13.1.3. Market Size by Emerging Therapies in the United States
- EU-5 Countries: Market Outlook
14.1.1. Total Market size of Interstitial Cystitis in Germany
14.1.2. Market Size by Current Therapies in Germany
14.1.3. Market Size by Emerging Therapies in Germany
14.2. France
14.2.1. Total Market size of Interstitial Cystitis in France
14.2.2. Market Size by Current Therapies in France
14.2.3. Market Size by Emerging Therapies in France
14.3. Italy
14.3.1. Total Market size of Interstitial Cystitis in Italy
14.3.2. Market Size by Current Therapies in Italy
14.3.3. Market Size by Emerging Therapies in Italy
14.4. Spain
14.4.1. Total Market Size of Interstitial Cystitis in Spain
14.4.2. Market Size by Current Therapies in Spain
14.4.3. Market Size by Emerging Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of Interstitial Cystitis in the United Kingdom
14.5.2. Market Size by Current Therapies in the United Kingdom
14.5.3. Market Size by Emerging Therapies in the United Kingdom
- Japan: Market Outlook
15.2. Market Size by Current Therapies in Japan
15.3. Market Size by Emerging Therapies in Japan
- Access and Reimbursement
- Market Drivers
- Market Barriers
- SWOT Analysis
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Related Reports:
Interstitial Cystitis - Pipeline Insights, 2020
The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
Interstitial Cystitis - Epidemiology Forecast to 2030
The Interstitial Cystitis epidemiology covered in the report provides historical as well as forecasted Interstitial Cystitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Comments
Post a Comment